Key terms
About ARCT
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ARCT news
Apr 09
7:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 01
7:15am ET
Buy Rating Affirmed for Arcturus: Promising Vaccine Commercialization and Rare Disease Pipeline Progress
Mar 26
7:15am ET
Optimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in Japan
Mar 20
7:30am ET
Analysts’ Top Healthcare Picks: Enliven Therapeutics (ELVN), Alphatec Holdings (ATEC)
Mar 20
6:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 19
6:12am ET
Arcturus Therapeutics’ Kostaive® Vaccine Succeeds in Phase III
Mar 11
6:46am ET
Arcturus Therapeutics price target raised to $87 from $81 at Canaccord
Mar 11
12:40am ET
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)
Mar 08
7:46am ET
Arcturus Therapeutics (ARCT) Gets a Buy from Piper Sandler
Mar 08
6:59am ET
Arcturus Therapeutics price target raised to $58 from $45 at Wells Fargo
Mar 08
6:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT)
Mar 08
5:50am ET
Analysts Offer Insights on Healthcare Companies: Cigna (CI) and Arcturus Therapeutics (ARCT)
Mar 07
4:03pm ET
Arcturus Therapeutics reports Q4 EPS (32c), consensus (99c)
Feb 22
8:47am ET
EC grants ‘orphan medicinal product designation’ to Arcturus’ ARCT-032 for CF
Feb 16
10:31am ET
Is Arcturus Therapeutics (NASDAQ: ARCT) the Hidden Gem of Small-Cap Biotech Stocks?
Feb 08
6:02am ET
Analysts Conflicted on These Healthcare Names: McKesson (MCK), Arcturus Therapeutics (ARCT) and Neurocrine (NBIX)
Feb 08
5:51am ET
Arcturus Therapeutics price target raised to $48 from $40 at Citi
Feb 08
4:55am ET
Arcturus Therapeutics management to meet with Piper Sandler
Feb 06
4:34pm ET
Arcturus Therapeutics management to meet with Piper Sandler
Feb 06
9:25am ET
Buy Rating on Arcturus Therapeutics Backed by Superior Vaccine Efficacy and Strong Product Pipeline
Feb 06
5:40am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 05
8:39am ET
Arcturus Therapeutics’ and CSL’s COVID-19 vaccine shows longer immune response
Jan 18
11:32am ET
Biotech Alert: Searches spiking for these stocks today
Jan 15
7:36am ET
3 Best Stocks to Buy Now, 1/15/2024, According to Top Analysts
Jan 13
10:15am ET
Buy Rating for Arcturus Therapeutics Amid Promising Vaccine Developments and Cost Advantages
Jan 10
7:18am ET
Piper Sandler Remains a Buy on Arcturus Therapeutics (ARCT)
No recent press releases are available for ARCT
ARCT Financials
Key terms
Ad Feedback
ARCT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ARCT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
